...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: 0.05 P-values -- A bridge too far ?

One possibility is the FDA may require another P3 for CVD, but in one or more patient groups selected for maximum effect (eg, low eGFR, or SGLT2/DPPD therapy) to get the result as soon as possible.

 

Share
New Message
Please login to post a reply